BioTelemetry (BEAT) Tops Q4 EPS by 5c

BioTelemetry (NASDAQ: BEAT) reported Q4 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $54 million versus the consensus estimate of $53.75 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• First Merchants Corp (FRME) Tops Q1 EPS by 3c
• Hess Corp. (HES) Tops Q1 EPS by 144c